what was the quantity purchased from other sources;

(f) whether it is a fact that M/s. Parke Davis has a monopoly of Diphendyramine in the market;

(g) what was the definition of monopoly taken by Kelkar Committee;

(h) whether it is a fact that Government provided the sale turn over data to Kelkar Committee; and

(i) if so, what was the sources?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) Sales turn-over of the individual cos., their purchases from other companies, the market share of individual companies, and the production of Small Scale units is not monitored by this Department.

(g) This information is contained in the main Report of the Kelkar Committee, a copy of which has already been laid on the Table of the House.

(h) No such data was furnished by the Department to the Kelkar Committee.

(i) Does not arise.

Steps to check hike in the prices of drugs

644. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 775 given in Rajya Sabha on the 25th July, 1991 and state:

(a) what are the names of medicines whose prices have come to the notice of Government on the higher side during the current year;

(b) what per cent of reductions Government made in each case due to intervention of Government;

(c) whether it is a fact that Government have made a study of the issue of trade commission being given by the manufacturers to the retailers; and

(d) if so, what is the average commission paid on scheduled and non-scheduled medicines and what is the average product, and discount being given?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Information is given below:—

Name of the medicine	Percentage reduction
1. ESCIPYRIN CABS 10'S	1·72%
2. Corbetta Tabs 10mg	8.89%
3. Corbetta Tabs 40mg	5·56%
4. Benadon Tabs 40mg 10'S	9·10%
5. Benadon 60×2ml	3·92%
6. Carbindon Tabs 100'S Cont.	12·5%

(c) and (d) A committee headed by Dr. I. Z. Bhatti was appointed to study the pattern of Trade margins in Pharmaceuticals Industry, whose final report is awaited.

Cost study of diclofenac Sodium by BICP

645. SHRI RAJNI RANJAN SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 401 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) when did Government ask BICP to conduct cost study of the Diclofenac Sodium;

(b) whether it is a fact that BICP has not so far studied costing of this drug; and

(c) if so, what action has been taken by Government and by when Government would fix the price of the drug?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The Government asked the BICP to conduct cost study of Diclofenac Sodium in October 1990.

(b) The report of BICP on cost-cum-technical study of this bulk drug has not been received by this Department till date.

(c) After getting the recommendation of BICP, the fair price of this bulk drug would be worked out and notified.

Reference of cases of drugs to directorate of revenue intelligence

664. SHRIMATI SATYA BAHIN:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 755 given in the Rajya Sabha on 25th July, 1991 and state:

(a) when each case of each company was referred to the Directorate of Revenue Intelligence;

(b) what action has been taken so far on this issue;

(c) how many complaints were received by Government alleging over invoicing and how many cases of overinvoicing has been detected durng the current year;

(d) whether it is a fact that instances of falsification of balance sheets by the producers of Sulphamethoxazole, Ethambutol, Trimethoprim and Cephalexin have come to the notice of Government; and

(e) if so, the details thereof and action taken on each?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (e) The details of complaints of instances over-invoicing were given in reply to Rajya Sabha Unstarred Question No. 1664 answered on 1-8-91. These complaints were forwarded to the Directorate of Revenue Intelligence for further investigation. Action would be taken after receiving findings from the Directorate of Revenue Intelligence.

Adjournment of M/s Glaxo's case

647. SHRI MODH. KHALEELUR RAHMAN:
SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 375 given in the Rajya Sabha on the 18th July, 1991 and state:

(a) whether it is a fact that Government sought adjournment many times in M/s. Glaxo's case;

(b) if so, how many times and on what ground adjournment was sought and how many times the company took adjournment;

(c) when did the company file writ petition and on what grounds and what is the progress;

(d) what are the grounds on which Delhi High Court gave interim stay and what steps have been taken by Government to get the stay vacated;